# Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)

> **NCT05660538** · PHASE2 · COMPLETED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 194 (actual)

## Conditions studied

- Diabetic Peripheral Neuropathy

## Interventions

- **DRUG:** Suzetrigine
- **DRUG:** Pregabalin
- **DRUG:** Placebo (matched to SUZ)
- **DRUG:** Placebo (matched to pregabalin)

## Key facts

- **NCT ID:** NCT05660538
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-12-20
- **Primary completion:** 2023-10-12
- **Final completion:** 2023-10-25
- **Target enrollment:** 194 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05660538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05660538, "Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05660538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*